New Drug Candidate Data Could Improve Renal Function

La Jolla Pharmaceutical Company (OTCBB:LJPC), which is developing therapeutics targeting galectin proteins, has released data detailing the ability of lead product candidate GCS-100 to improve renal function.

As quoted in the market news:

“This retrospective analysis emphasizes the fact that GCS-100 treatment in patients with reduced renal function have improvement in estimated glomerular filtration rate. This analysis supports the upcoming Phase 2a trial of GCS-100 in CKD, which we hope will confirm the effect,” said President and CEO George Tidmarsh.

Read the full La Jolla (OTCBB:LJPC) press release here